新疆石河子地区2009～2017年前列腺癌流行趋势分析
|
摘要
目的:前列腺癌是男性常见恶性肿瘤之一,危害逐年加重。本文旨在分析石河子地区2009～2017年前列腺癌发病和死亡趋势,为防控工作提供依据。方法:利用2009～2017年石河子肿瘤登记数据,计算前列腺癌发病率、死亡率及年度变化百分比(APC)指标,分析其时间变化趋势。结果:2009～2017年石河子地区前列腺癌发病率、中标率、世标率和累计率(0～74岁)分别为16. 94/10万、10. 33/10万、8. 98/10万、2. 29/10万;死亡相对应指标分别为9. 03/10万、5. 39/10万、4. 72/10万、0. 49/10万。2009～2017年石河子地区前列腺癌发病率和死亡率整体呈上升趋势,APC分别为16. 69%、19. 71%(两者均为P <0. 05)。其中2011～2017年,60岁以上人群发病率和死亡率的增加值占比分别为86. 20%和89. 30%,峰值由70～74岁移至80～84岁。结论:石河子地区前列腺癌发病率和死亡率2009～2017年呈上升趋势,集中在60岁以上老年人群,且峰值后移,未呈年轻化趋势。
Objective:To analyze the trend in the prevalence and mortality of prostate cancer in Shihezi,Xinjiang from 2009 to2017 and provide some evidence for the prevention and control of the malignance.Methods:We collected the data on the cancer registries in the Shihezi area between 2009 and 2017,calculated the incidence and mortality rates of prostate cancer,and analyzed the annual percent change(APC) and prevalence trend of the disease.Results:The crude incidence rate,age-standardized incidence rate by Chinese standard population(ASIRC),age-standardized incidence rate by world standard population(ASIRW) and cumulative incidence rate of prostate cancer(in 0-74-year-olds) in Shihezi between 2009 and 2017 were 16.94,10.33,8.98 and 2.29 per100 000,respectively.The crude mortality rate,age-standardized mortality rate by Chinese standard population(ASMRC),agestandardized mortality rate by world standard population(ASMRW) and cumulative incidence rate(in 0-74-year-olds) were 9.03,5.39 and 4.72 and 0.49 per 100 000,respectively.Both the incidence and mortality rates showed an increasing trend from 2009 to2017,with an APC of 16.69%(P < 0.05) and 19.71%(P < 0.05),respectively.From 2011 to 2017,the increase rates of inci-dence and mortality of prostate cancer in the > 60-year-olds were 86.20% and 89.30%,with the peak values shifted from the 70-74 to the 80-84 years old males.Conclusion:The incidence and mortality of prostate cancer in Shihezi showed an increasing trend from 2009 to 2017,chiefly in the males aged over 60 years,with the peak value moving towards an older age.
Objective:To analyze the trend in the prevalence and mortality of prostate cancer in Shihezi,Xinjiang from 2009 to2017 and provide some evidence for the prevention and control of the malignance.Methods:We collected the data on the cancer registries in the Shihezi area between 2009 and 2017,calculated the incidence and mortality rates of prostate cancer,and analyzed the annual percent change(APC) and prevalence trend of the disease.Results:The crude incidence rate,age-standardized incidence rate by Chinese standard population(ASIRC),age-standardized incidence rate by world standard population(ASIRW) and cumulative incidence rate of prostate cancer(in 0-74-year-olds) in Shihezi between 2009 and 2017 were 16.94,10.33,8.98 and 2.29 per100 000,respectively.The crude mortality rate,age-standardized mortality rate by Chinese standard population(ASMRC),agestandardized mortality rate by world standard population(ASMRW) and cumulative incidence rate(in 0-74-year-olds) were 9.03,5.39 and 4.72 and 0.49 per 100 000,respectively.Both the incidence and mortality rates showed an increasing trend from 2009 to2017,with an APC of 16.69%(P < 0.05) and 19.71%(P < 0.05),respectively.From 2011 to 2017,the increase rates of inci-dence and mortality of prostate cancer in the > 60-year-olds were 86.20% and 89.30%,with the peak values shifted from the 70-74 to the 80-84 years old males.Conclusion:The incidence and mortality of prostate cancer in Shihezi showed an increasing trend from 2009 to 2017,chiefly in the males aged over 60 years,with the peak value moving towards an older age.
引文
[1]韩苏军.中国前列腺癌发病及死亡现状和流行趋势分析(硕士论文).北京:北京协和医学院,2015.
[2]韩苏军,张思维,陈万青,等.中国前列腺癌发病现状和流行趋势分析.临床肿瘤学杂志,2013,18(4):330-334.
[3]Scosyrev E,Messing EM,Mohile S,et al.Prostate cancer in the elderly:Frequency of advanced disease at presentation and disease-specific mortality.Cancer.2012,118(12):3062-3070.
[4]Sun L,Caire AA,Robertson CN,et al.Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.J Urol.2009,182(5):2242-2248.
[5]Curado MP,Edwards B,Shin HR,Storm H,et al.Cancer incidence in five continents,Vol.Ⅸ.Lyon:IARC Scientific Publication,2008.
[6]项永兵,张薇,高立峰,等.恶性肿瘤发病率的时间趋势分析方法.中华流行病学杂志,2004,25(2):173-177.
[7]Sharma D.The future in the past,or the management of invasive prostatic cancer in the Third World.BJU Int,2004,93(3):422-423.
[8]刘碧天,吴斌.老年前列腺癌患者身体状态评估的研究进展.中华男科学杂志,2017,23(12):1132-1137.
[9]陈万青,孙可欣,郑荣寿,等.2014年中国分地区恶性肿瘤发病和死亡分析.中国肿瘤,2018,27(1):1-14.
[10]梁彩花,柳青,周芳坚,等.广东地区前列腺癌与饮食因素的病例对照研究.现代预防医学,2007,34(9):1646-1649,1655.
[11]沈志坚,谢红林,黄啸,等.前列腺微小癌26例临床分析.2006年浙江省泌尿外科学学术年会.杭州:浙江省医学会,2006.
[12]吴文娟.石河子地区老龄人口现状及社会保障研究(硕士论文).石河子:石河子大学,2013.
[13]曹万里,孙福康.以PSA为基础的前列腺癌筛查研究的探讨.中华男科学杂志,2013,19(6):559-562.
[14]李日.2013-2015年吉林省居民恶性肿瘤死因流行病学分析(硕士论文).长春:吉林大学,2017.
[15]牟睿宇,李小江.前列腺癌实验室诊断方法研究进展.中华男科学杂志,2017,23(4):372-375.
[16]张树江,孙祖越.PSA与前列腺癌发展和转移相关性的研究进展.中华男科学杂志,2018,24(5):457-461.
[2]韩苏军,张思维,陈万青,等.中国前列腺癌发病现状和流行趋势分析.临床肿瘤学杂志,2013,18(4):330-334.
[3]Scosyrev E,Messing EM,Mohile S,et al.Prostate cancer in the elderly:Frequency of advanced disease at presentation and disease-specific mortality.Cancer.2012,118(12):3062-3070.
[4]Sun L,Caire AA,Robertson CN,et al.Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.J Urol.2009,182(5):2242-2248.
[5]Curado MP,Edwards B,Shin HR,Storm H,et al.Cancer incidence in five continents,Vol.Ⅸ.Lyon:IARC Scientific Publication,2008.
[6]项永兵,张薇,高立峰,等.恶性肿瘤发病率的时间趋势分析方法.中华流行病学杂志,2004,25(2):173-177.
[7]Sharma D.The future in the past,or the management of invasive prostatic cancer in the Third World.BJU Int,2004,93(3):422-423.
[8]刘碧天,吴斌.老年前列腺癌患者身体状态评估的研究进展.中华男科学杂志,2017,23(12):1132-1137.
[9]陈万青,孙可欣,郑荣寿,等.2014年中国分地区恶性肿瘤发病和死亡分析.中国肿瘤,2018,27(1):1-14.
[10]梁彩花,柳青,周芳坚,等.广东地区前列腺癌与饮食因素的病例对照研究.现代预防医学,2007,34(9):1646-1649,1655.
[11]沈志坚,谢红林,黄啸,等.前列腺微小癌26例临床分析.2006年浙江省泌尿外科学学术年会.杭州:浙江省医学会,2006.
[12]吴文娟.石河子地区老龄人口现状及社会保障研究(硕士论文).石河子:石河子大学,2013.
[13]曹万里,孙福康.以PSA为基础的前列腺癌筛查研究的探讨.中华男科学杂志,2013,19(6):559-562.
[14]李日.2013-2015年吉林省居民恶性肿瘤死因流行病学分析(硕士论文).长春:吉林大学,2017.
[15]牟睿宇,李小江.前列腺癌实验室诊断方法研究进展.中华男科学杂志,2017,23(4):372-375.
[16]张树江,孙祖越.PSA与前列腺癌发展和转移相关性的研究进展.中华男科学杂志,2018,24(5):457-461.